Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

The immunotherapeutic agent ipilimumab has helped address a significant unmet need in the treatment of advanced melanoma. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte antigen-4 (CTLA-4), thereby augmenting antitumor immune responses. After decades in which a nu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolchok, Jedd D, Hodi, F Stephen, Weber, Jeffrey S, Allison, James P, Urba, Walter J, Robert, Caroline, O'Day, Steven J, Hoos, Axel, Humphrey, Rachel, Berman, David M, Lonberg, Nils, Korman, Alan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals Inc. 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910157/
https://www.ncbi.nlm.nih.gov/pubmed/23772560
http://dx.doi.org/10.1111/nyas.12180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910157/
https://www.ncbi.nlm.nih.gov/pubmed/23772560
http://dx.doi.org/10.1111/nyas.12180

Ejemplares similares